AUTL
Autolus Therapeutics plc NASDAQ Listed Jun 22, 2018$1.66
+11.41%
vs $1.49
Mkt Cap $441.8M
52w Low $1.21
30.6% of range
52w High $2.68
50d MA $1.58
200d MA $1.53
P/E (TTM)
-1.5x
EV/EBITDA
—
P/B
2.5x
Debt/Equity
2.0x
ROE
-161.4%
P/FCF
-1.5x
RSI (14)
44.30
ATR (14)
$0.12
Beta
2.03
50d MA
$1.58
200d MA
$1.53
Avg Volume
1.5M
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
The MediaWorks · London, X0 W12 7FP · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | BMO | -0.26 | -0.34 | -30.8% | 1.21 | +1.7% | +5.0% | +8.7% | +0.0% | +2.2% | -1.4% | — |
| Nov 12, 2025 | BMO | -0.23 | -0.30 | -30.4% | 1.36 | -0.7% | -5.9% | +7.0% | -2.2% | -3.7% | -1.6% | — |
| Aug 12, 2025 | BMO | -0.24 | -0.18 | +25.0% | 2.15 | +0.0% | -14.4% | +0.5% | -3.8% | +5.6% | -4.8% | — |
| May 8, 2025 | BMO | -0.24 | -0.26 | -8.3% | 1.35 | +0.7% | -2.2% | +2.3% | -5.9% | -3.9% | +5.7% | — |
| Mar 20, 2025 | BMO | -0.21 | -0.09 | +57.1% | 1.68 | +3.0% | +1.2% | +0.6% | -5.3% | +0.6% | +1.2% | — |
| Nov 12, 2024 | BMO | -0.21 | -0.31 | -47.6% | 3.33 | +2.1% | -1.2% | -8.5% | +2.3% | -2.9% | -1.3% | — |
| Aug 8, 2024 | BMO | -0.19 | -0.22 | -15.8% | 3.64 | +4.4% | +0.8% | +0.3% | +1.9% | -4.3% | +4.5% | — |
| May 17, 2024 | BMO | -0.10 | -0.24 | -140.0% | 4.39 | -0.5% | -8.4% | -3.7% | -0.8% | +0.8% | +1.3% | — |
| Mar 14, 2024 | BMO | -0.26 | -0.44 | -69.2% | 5.70 | +0.0% | +2.1% | +6.7% | -0.2% | +5.6% | -4.6% | — |
| Nov 2, 2023 | BMO | -0.24 | -0.26 | -8.3% | 3.39 | -5.0% | +20.6% | -9.5% | -0.5% | +0.5% | -5.7% | — |
| Aug 3, 2023 | BMO | -0.22 | -0.26 | -18.2% | 3.00 | +0.7% | +0.7% | -5.3% | +3.8% | +0.7% | -2.7% | — |
| May 4, 2023 | BMO | -0.28 | -0.23 | +17.9% | 1.92 | +0.5% | -1.6% | -0.5% | +2.7% | -1.0% | -3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Needham | Maintains | Buy → Buy | — | $1.49 | $1.49 | +0.0% | -1.3% | +1.4% | -1.3% | +0.7% | +0.7% |
| Mar 31 | Mizuho | Maintains | Outperform → Outperform | — | $1.27 | $1.31 | +3.1% | +8.7% | +0.0% | +2.2% | -1.4% | -2.2% |
| Mar 27 | Needham | Maintains | Buy → Buy | — | $1.29 | $1.21 | -6.2% | -6.2% | +5.0% | +8.7% | +0.0% | +2.2% |
| Jan 12 | Needham | Maintains | Buy → Buy | — | $1.81 | $1.79 | -1.1% | -17.1% | -8.7% | +3.6% | +1.4% | -4.2% |
| Dec 29 | Needham | Maintains | Buy → Buy | — | $1.67 | $1.70 | +1.8% | +12.0% | +5.3% | +1.0% | -6.0% | -0.5% |
| Dec 12 | Needham | Maintains | Buy → Buy | — | $1.59 | $1.61 | +1.3% | +1.3% | +0.6% | -1.2% | -2.5% | +0.6% |
| Nov 3 | Needham | Maintains | Buy → Buy | — | $1.55 | $1.56 | +0.6% | +0.6% | -9.6% | -1.4% | -2.2% | -2.2% |
| Oct 20 | Needham | Maintains | Buy → Buy | — | $1.62 | $1.70 | +4.9% | +4.9% | -4.1% | -4.9% | -3.2% | +2.0% |
| Aug 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.15 | $2.15 | +0.0% | -14.4% | +0.5% | -3.8% | +5.6% | -4.8% |
| Jul 21 | Needham | Maintains | Buy → Buy | — | $2.41 | $2.57 | +6.6% | +0.8% | +7.4% | +2.7% | -1.5% | -4.5% |
| Jun 12 | Needham | Maintains | Buy → Buy | — | $2.24 | $2.24 | +0.0% | -4.0% | -1.4% | -3.3% | -1.0% | +1.5% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $1.21 | $1.23 | +1.7% | -5.8% | +19.3% | -1.5% | +4.5% | -3.6% |
| Apr 1 | Truist | Maintains | Buy → Buy | — | $1.55 | $1.57 | +1.3% | -9.0% | +11.3% | -3.8% | -11.9% | -1.5% |
| Mar 21 | Wells Fargo | Maintains | Overweight → Overweight | — | $1.68 | $1.73 | +3.0% | +1.2% | +0.6% | -5.3% | +0.6% | +1.2% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $2.36 | $2.31 | -2.1% | -2.5% | -3.9% | +5.4% | -4.7% | +0.0% |
| Dec 9 | Needham | Maintains | Buy → Buy | — | $2.94 | $2.93 | -0.3% | +0.3% | -2.7% | +1.0% | -7.2% | -7.4% |
| Dec 5 | Needham | Maintains | Buy → Buy | — | $3.05 | $3.05 | +0.0% | -4.3% | +0.7% | +0.3% | -2.7% | +1.0% |
| Nov 18 | Goldman Sachs | Upgrade | Neutral → Buy | — | $3.08 | $3.24 | +5.2% | -2.9% | -1.3% | -5.1% | +1.4% | +3.5% |
| Nov 15 | Redburn Atlantic | Upgrade | Neutral → Buy | — | $3.01 | $3.16 | +5.0% | +2.3% | -2.9% | -1.3% | -5.1% | +1.4% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $3.33 | $3.40 | +2.1% | -1.2% | -8.5% | +2.3% | -2.9% | -1.3% |
| Nov 12 | Needham | Maintains | Buy → Buy | — | $3.51 | $3.72 | +6.0% | -5.1% | -1.2% | -8.5% | +2.3% | -2.9% |
| Nov 11 | Needham | Maintains | Buy → Buy | — | $3.73 | $3.95 | +5.9% | -5.9% | -5.1% | -1.2% | -8.5% | +2.3% |
| Jun 17 | Needham | Maintains | Buy → Buy | — | $4.50 | $4.50 | +0.0% | -4.2% | -9.5% | -1.0% | -0.8% | -2.9% |
| Jun 3 | Needham | Maintains | Buy → Buy | — | $4.19 | $4.25 | +1.4% | +7.4% | -6.9% | +2.4% | -0.2% | -6.5% |
| May 17 | Needham | Maintains | Buy → Buy | — | $4.07 | $4.50 | +10.6% | +7.9% | -8.4% | -3.7% | -0.8% | +0.8% |
| Apr 12 | Needham | Maintains | Buy → Buy | — | $5.33 | $5.21 | -2.3% | -5.8% | -2.4% | -0.8% | -0.4% | -0.8% |
| Apr 9 | Truist | Maintains | Buy → Buy | — | $5.43 | $5.54 | +2.0% | +0.0% | -5.2% | +3.5% | -5.8% | -2.4% |
| Mar 18 | Truist | Maintains | Buy → Buy | — | $5.82 | $5.82 | +0.0% | +6.7% | -0.2% | +5.6% | -4.6% | +1.1% |
| Mar 14 | Needham | Maintains | Buy → Buy | — | $5.48 | $5.58 | +1.8% | +4.0% | +2.1% | +6.7% | -0.2% | +5.6% |
| Feb 12 | Needham | Maintains | Buy → Buy | — | $6.38 | $6.52 | +2.2% | +9.6% | -2.0% | +5.8% | -2.3% | -3.5% |
| Jan 22 | Needham | Maintains | Buy → Buy | — | $6.11 | $6.26 | +2.5% | -5.9% | -4.0% | +4.0% | +3.7% | -0.2% |
| Dec 13 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.50 | $4.80 | +6.7% | +7.8% | +2.5% | +0.8% | +3.4% | +0.4% |
| Nov 29 | Needham | Maintains | Buy → Buy | — | $4.55 | $4.63 | +1.8% | -10.3% | +4.9% | -2.1% | -6.9% | +2.8% |
| Oct 25 | Needham | Maintains | Buy → Buy | — | $2.69 | $2.76 | +2.6% | +3.7% | -3.6% | -1.9% | +3.0% | +3.7% |
| Aug 17 | Truist | Maintains | Buy → Buy | — | $2.64 | $2.72 | +3.0% | +11.4% | +7.1% | +2.5% | +1.2% | +2.8% |
| Jun 5 | Needham | Maintains | Buy → Buy | — | $2.90 | $2.91 | +0.3% | +0.7% | +0.7% | +0.3% | -1.0% | -1.7% |
| Jun 2 | Needham | Maintains | Buy → Buy | — | $3.13 | $3.22 | +2.9% | -7.3% | +0.7% | +0.7% | +0.3% | -1.0% |
| May 5 | Needham | Maintains | Buy → Buy | — | $1.92 | $1.93 | +0.5% | -1.6% | -0.5% | +2.7% | -1.0% | -3.1% |
| May 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $1.92 | $1.93 | +0.5% | -1.6% | -0.5% | +2.7% | -1.0% | -3.1% |
| Apr 28 | Needham | Maintains | Buy → Buy | — | $1.73 | $1.73 | +0.0% | +4.6% | +2.8% | +5.4% | +0.0% | -2.0% |
| Apr 21 | Needham | Maintains | Buy → Buy | — | $1.81 | $1.84 | +1.7% | -0.6% | -1.1% | -2.8% | -5.2% | +5.5% |
| Mar 8 | Mizuho | Maintains | Buy → Buy | — | $1.92 | $1.92 | +0.0% | +6.2% | -2.5% | -4.5% | +6.3% | +4.0% |
| Mar 7 | Needham | Maintains | Buy → Buy | — | $1.91 | $2.00 | +4.7% | +0.5% | +6.2% | -2.5% | -4.5% | +6.3% |
| Dec 9 | Needham | Maintains | Buy → Buy | — | $2.99 | $1.90 | -36.5% | -38.1% | -4.3% | -1.7% | +5.2% | +1.1% |
| Aug 5 | Needham | Maintains | Buy → Buy | — | $3.25 | $3.22 | -0.9% | +7.1% | -4.6% | -0.6% | +2.4% | +2.4% |
| Jun 14 | Truist | Maintains | Buy → Buy | — | $2.28 | $2.29 | +0.4% | -1.3% | -9.3% | +1.0% | +7.8% | +7.7% |
| May 6 | Needham | Maintains | Buy → Buy | — | $5.20 | $5.31 | +2.1% | -1.9% | +5.3% | -11.0% | +4.4% | +35.5% |
| Mar 10 | Redburn | Downgrade | Buy → Neutral | — | $6.34 | $6.20 | -2.2% | -2.7% | +4.5% | +3.9% | -1.0% | +5.0% |
| Mar 10 | Redburn Partners | Downgrade | Buy → Neutral | — | $6.34 | $6.20 | -2.2% | -2.7% | +4.5% | +3.9% | -1.0% | +5.0% |
| Mar 9 | Redburn | Downgrade | Buy → Neutral | — | $6.16 | $6.24 | +1.3% | +2.9% | -2.7% | +4.5% | +3.9% | -1.0% |
No insider trades available.
8-K · 8.01
!! High
Autolus Therapeutics plc -- 8-K 8.01: Material Event / Announcement
Autolus Therapeutics published its 2025 annual report and scheduled its shareholder meeting for June 29, 2026, providing investors with full-year financial results and governance documentation.
Jun 9
8-K · 2.02
!! High
Autolus Therapeutics plc -- 8-K 2.02: Earnings Results
May 14
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Syncona Portfolio Ltd | 16,640,720 | $23M | — | Mar 2026 |
| 2 | Schroder Investment Management Group | 9,489,345 | $12M | — | Mar 2026 |
| 3 | Laurion Capital Management Lp | 3,316,626 | $7M | — | Dec 2025 |
| 4 | Morgan Stanley | 2,794,502 | $6M | Added | Dec 2025 |
| 5 | Bnp Paribas Asset Management Holding S.a. | 3,361,156 | $5M | — | Mar 2026 |
| 6 | Renaissance Technologies Llc | 2,299,499 | $3M | Reduced | Mar 2026 |
| 7 | Bank Of America Corp /de/ | 1,844,671 | $3M | Reduced | Mar 2026 |
| 8 | Ubs Group Ag | 1,305,779 | $2M | Added | Mar 2026 |
| 9 | Alphabet Inc. | 698,262 | $1M | — | Dec 2025 |
| 10 | Jane Street Group, Llc | 681,000 | $1M | Reduced | Dec 2025 |
| 11 | Jpmorgan Chase & Co | 935,403 | $1M | Reduced | Mar 2026 |
| 12 | Marex Group Plc | 542,857 | $749K | New | Mar 2026 |
| 13 | Citadel Advisors Llc | 459,404 | $634K | Reduced | Mar 2026 |
| 14 | Point72 Asset Management | 426,983 | $589K | Added | Mar 2026 |
| 15 | Susquehanna International Group, Llp | 399,143 | $551K | Reduced | Mar 2026 |
| 16 | Privium Fund Management B.v. | 363,430 | $502K | Added | Mar 2026 |
| 17 | Aubrey Capital Management Ltd | 225,201 | $445K | Reduced | Dec 2025 |
| 18 | Edentree Asset Management Ltd | 300,000 | $414K | — | Mar 2026 |
| 19 | Wells Fargo & Company/mn | 207,856 | $287K | New | Mar 2026 |
| 20 | Millennium Management | 204,728 | $283K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 7
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Biotechnology ETF | 1,321,681 | $2M | Mar 2026 |
| 2 | BlackRock Health Sciences Opportunities Portfolio | 728,967 | $1M | Feb 2026 |
| 3 | Fidelity Nasdaq Composite Index Fund | 110,578 | $189K | Feb 2026 |
| 4 | Invesco NASDAQ Future Gen 200 ETF | 47,044 | $80K | Feb 2026 |
| 5 | Invesco Nasdaq Biotechnology ETF | 11,218 | $19K | Feb 2026 |
| 6 | ProShares Ultra Nasdaq Biotechnology | 9,262 | $16K | Feb 2026 |
| 7 | iShares Health Innovation Active ETF | 3,256 | $4K | Jan 2026 |
Valuation
Market Cap
$441.8M
Enterprise Value
$411.3M
P/E (TTM)
-1.52x
Forward P/E
—
PEG Ratio
-0.08x
P/B
2.48x
P/S
4.77x
P/FCF
-1.46x
EV/EBITDA
—
Shares Out
266.1M
Financials (TTM)
Revenue
$92.6M
Net Income
-$288.8M
EBITDA
-$230.8M
Free Cash Flow
-$303.3M
Op Cash Flow
-$283.6M
EPS Basic
$-1.08
EPS Diluted
$-1.09
EPS Forward
$-0.91
Gross Margin
-11.2%
Op Margin
-285.9%
Net Margin
-311.9%
Balance Sheet
Total Assets
$589.1M
Total Liab.
$410.9M
Total Equity
$178.1M
Cash
$300.7M
LT Debt
$270.2M
Book Value/Sh
$0.67
Debt/Equity
1.97x
Current Ratio
5.94
Quick Ratio
5.48
Returns & Growth
ROE
-161.4%
ROA
-48.8%
ROIC
-53.1%
Rev Growth YoY
+646.7%
EPS Growth YoY
-24.1%
Price Returns
2W
+17.6%
1M
+32.6%
3M
+9.4%
6M
+32.6%
12M
+6.9%
Technicals
52W High
$2.68
52W Low
$1.21
50d MA
$1.58
200d MA
$1.53
RSI (14)
44.30
ATR (14)
$0.12
Beta
2.03
Avg Volume
1.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.87
High
$11.00
Low
$7.60
Median
$8.00
Data updated apr 26, 2026 9:42am
· Source: financialmodelingprep.com